US8562967B2 - Stable liquid formulations of G-CSF - Google Patents

Stable liquid formulations of G-CSF Download PDF

Info

Publication number
US8562967B2
US8562967B2 US12/675,776 US67577608A US8562967B2 US 8562967 B2 US8562967 B2 US 8562967B2 US 67577608 A US67577608 A US 67577608A US 8562967 B2 US8562967 B2 US 8562967B2
Authority
US
United States
Prior art keywords
csf
concentration
medicament
receptacle
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US12/675,776
Other languages
English (en)
Other versions
US20100216698A1 (en
Inventor
Walter Hinderer
Heinz Lubenau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ratiopharm GmbH
Original Assignee
Biogenerix GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102007040932A external-priority patent/DE102007040932A1/de
Application filed by Biogenerix GmbH filed Critical Biogenerix GmbH
Assigned to BIOGENERIX AG reassignment BIOGENERIX AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LUBENAU, HEINZ, HINDERER, WALTER
Publication of US20100216698A1 publication Critical patent/US20100216698A1/en
Assigned to BIOGENERIX AG reassignment BIOGENERIX AG CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED ON REEL 024247 FRAME 0579. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNEE ADDRESS IS GRAF-ARCO-STR. 3, 89079 ULM, GERMANY. Assignors: LUBENAU, HEINZ, HINDERER, WALTER
Application granted granted Critical
Publication of US8562967B2 publication Critical patent/US8562967B2/en
Assigned to RATIOPHARM GMBH reassignment RATIOPHARM GMBH MERGER (SEE DOCUMENT FOR DETAILS). Assignors: BIOGENERIX GMBH
Assigned to BIOGENERIX GMBH reassignment BIOGENERIX GMBH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: BIOGENERIX AG
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Objects of the present invention are stable, aqueous liquid formulations of G-CSF, substantially consisting of G-CSF and a sugar alcohol, a surfactant, a buffer substance at a pH value of about 4.1 to 4.4, and optionally also amino acids and/or glycerol and/or carbohydrates and/or preservatives.
  • the admixture of compounds having a high molecular weight can also be problematic.
  • Polymers can be accumulated in the body due to their high molecular mass and can therefore remain in the body for a long time, in case there is no biodegradation. This is, in particular, to be feared in case of subcutaneous application, as removal and distribution via the bloodstream is much more delayed in comparison to intravenous application.
  • polymers can also have antigenic properties.
  • the purity of polymers is difficult to ensure due to the catalysts used for production or due to the presence of monomers and other polymer fragments. The use of polymers in liquid pharmaceutical dosage forms is thus to be avoided as far as possible, in particular with subcutaneously applicable dosage forms.
  • surfactants for stabilizing G-CSF is principally to be avoided from a medical point of view as said surfactants may trigger local irritations.
  • Formulations having a very low pH value in particular in case of a subcutaneous application, can also lead to local incompatibilities in patients, e.g. pain and local tissue irritation, as said pH value lies below the physiological range from pH 7.0 to 7.5 that is present in the tissue.
  • the problem underlying the present invention is to provide a liquid dosage form for G-CSF which does not show the above-described disadvantages of the hitherto known dosage forms.
  • the pharmaceutical preparation should be stable over a long time period as well as physiologically acceptable. It should, in particular, be suitable for self-application by patients and it should be characterized by the capability to avoid undesired irritations of the skin and pain at the injection site often occurring along with the self-application of medicaments by means of an injection or infusion.
  • the present invention relates to stable, aqueous liquid formulations of G-CSF substantially consisting of G-CSF and a sugar alcohol, a surfactant at a concentration of about 0.04 to 0.06 mg/ml, acetate at a concentration of about 5 to 20 mM as a buffer substance at a pH value of about 4.1 to 4.4.
  • a surfactant at a concentration of about 0.04 to 0.06 mg/ml
  • acetate at a concentration of about 5 to 20 mM
  • a buffer substance at a pH value of about 4.1 to 4.4
  • amino acids and/or glycerol and/or carbohydrates and/or preservatives can be used.
  • the liquid formulation according to the present invention can contain further pharmaceutically conventional excipients. However, the absence of said and/or other excipients is preferred.
  • G-CSF liquid formulations of the composition 0.6 mg/ml G-CSF, 10 mM acetate buffer, 0.004% (w/v) Tween 80 and 5% (w/v) D-sorbitol having a pH value of 4.0 and 4.2 were used as comparative formulations in studies for the stability of G-CSF formulations under impact of mechanical stress and after freezing and thawing of G-CSF formulations with succinate buffer having a pH value of 5.0 and 0.02% (w/v) Tween 20. According to these studies, the G-CSF formulations with acetate buffer were less stable, so that it did not appear sensible to further study such acetate-buffered compositions, let alone to consider them as candidate medicaments.
  • acetate-buffered G-CSF formulations having a pH>4.0 with respect to stability at storage temperatures in a refrigerator and at 40° C., i.e. in the range of body temperature were surprisingly found as well as a surprisingly good acceptability in patients, as less skin irritations occurred in comparison to commercially available medicaments.
  • the liquid formulations according to the present invention further have the advantage of preferably being free of protein-like or polymeric excipients, the use of which can be problematic from a medical point of view. As shown by the clinical studies illustrated in the Examples, they further have the advantage of being well acceptable and applicable in a substantially pain-free manner.
  • the G-CSF liquid formulation according to the present invention is preferably free of amino acids and/or additional proteins, such as serum albumin. In one embodiment, the liquid formulation according to the present invention is free of methionine.
  • surfactant in a range from 0.05 to 0.06 mg/ml, particularly preferred about 0.06 mg/ml will be used.
  • the surfactant to be used is preferably polysorbate, particularly preferably polysorbate 80, also known as Tween 80.
  • the G-CSF-containing dosage forms according to the present invention contain the agent in an amount that is sufficient for achieving a therapeutic effect.
  • agent concentrations ranging from 0.01 to 5 mg/ml are used, preferably 0.1 to 1 mg/ml, 0.3 to 0.8 mg/ml, and particularly preferred a concentration of about 0.6 mg/ml is used.
  • dosages of 0.3 mg/0.5 ml and 0.48 mg/0.8 ml turned out to be particularly preferable.
  • acetic acid is employed as a buffer substance.
  • the buffer substance is provided in form of its free acid.
  • the desired pH value of the solution is adjusted by the addition of bases, like for example alkali hydroxides, earth alkali hydroxides or ammonium hydroxide.
  • bases like for example alkali hydroxides, earth alkali hydroxides or ammonium hydroxide.
  • the use of sodium hydroxide is preferred.
  • the concentrations of the buffer substance acetic acid in the ready-to-use liquid dosage form range from about 5 to 20 mMol/l.
  • concentrations of said acid i.e. acetate
  • acetate is intended to also comprise undissociated acetic acid.
  • buffer concentrations and pH values are employed: 7.5 to 15 mMol, particularly preferably 10 mMol acetate and pH 4.1 to 4.4; preferably pH 4.15 to 4.3; and in particular pH 4.2.
  • the G-CSF used in the liquid formulations according to the present invention basically relates to all G-CSF molecules produced by means of recombinant methods as well as to variations thereof.
  • the term G-CSF or G-CSF variant according to the present invention includes all naturally occurring variants of G-CSF as well as G-CSF proteins derived therefrom and modified by means of recombinant DNA technology, in particular fusion proteins also containing other protein sequences besides the G-CSF portion.
  • Particularly preferred in this sense is a G-CSF mutein having an N-terminal Met residue at position-1, which is generated by the expression in prokaryotic cells.
  • a recombinant methionine-free G-CSF variant that can be produced according to WO 91/11520.
  • G-CSF variant is understood to denote such G-CSF molecules in which one or more amino acids can be deleted or substituted by other amino acids, wherein the substantial characteristics of G-CSF are maintained to a large extent.
  • Suitable G-CSF muteins are described, for example, in EP 0 456 200.
  • the G-CSF that is present in the liquid formulations according to the present invention is not glycosylated.
  • the admixture of isotonizing excipients is appropriate, unless isotonia can already be achieved with the osmotic properties of the agent and of the excipients employed for stabilizing.
  • particularly non-ionized, well acceptable excipients like for example mannitol, glycerol or other sugar alcohols, are employed.
  • sorbitol is preferred, which is particularly advantageous for the acceptability of the liquid formulations according to the present invention.
  • the sugar alcohol is present in the liquid formulation at a concentration ranging from about 2.5 to 7.5% (w/v), particularly preferably at a concentration of about 5% (w/v).
  • the admixture of salts for adjusting isotonia is not advantageous as high concentrations of salt or ions enhance the aggregate formation of G-CSF. Therefore, salts are advantageously admixed in small amounts.
  • the buffer concentrations are measured in such a way that the pH-stabilizing effect is achieved while the ionic strength is kept at the lowest possible level.
  • the buffer concentrations are within a range of up to 20 mMol, in particular less than 15 mMol.
  • the ready-to-use injection solutions may contain further conventional excipients or additives.
  • Antioxidants like for example glutathione, ascorbic acid or similar substances, chaotropic excipients, like for example urea, or amino acids, like for example methionine, arginine, lysine, ornithine and the like, can be admixed.
  • the aqueous liquid formulation of G-CSF according to the present invention is prepared in form of an injection or infusion solution and substantially consists of human, non-glycosylated methionyl-G-CSF at a concentration of about 0.6 mg/ml and sorbitol at a concentration of about 5% (w/v), polysorbate 80 at a concentration of about 0.06 mg/ml, and acetate at a concentration of about 10 mM as a buffer substance at a pH value of about 4.2.
  • liquid formulations of G-CSF according to the present invention can be used according to the product information of Neupogen®, in particular with regard to dosage, administration and medical indication, as the use of highly purified, non-glycosylated G-CSF protein like filgrastim, which is produced in a laboratory strain of E. coli K12, is also preferred in liquid formulations according to the present invention.
  • the liquid formulations according to the present invention are advantageously used as a medicament for the treatment of diseases that are known to be treatable by administration of G-CSF, like cancer, adverse side effects caused by cytotoxic chemotherapy, accompanying therapy of diseases, wherein a mobilization of peripheral blood precursor cells is required, severe chronic neutropenia (SCN), HIV infection, and the like.
  • the present invention in particular relates to medicaments comprising one of the G-CSF liquid formulations described above.
  • the G-CSF composition according to the present invention is intended for the preparation of a medicament for the treatment of neurological indications, like a damage of the central nervous system, for example subsequent to an acute cerebrovascular accident, wherein severe secondary damages can be alleviated or prevented by means of early administration, for example in form of a bolus.
  • the liquid formulations according to the present invention are intended as a medicament, preferably for subcutaneous or intravenous administration, for example by injection with prefilled syringes or by infusion, in case a long-term continuous administration of G-CSF is desirable.
  • the liquid formulation of G-CSF according to the present invention is stable over a long time period and can basically be stored in any suitable receptacle. Accordingly, the present invention also relates to a receptacle containing one of the liquid formulations of G-CSF described above or in the Examples. Preferably, at least one surface of the receptacle which is in contact with the liquid formulation is coated with a material consisting of polytetrafluoroethylene or ethylene-tetrafluoroethylene (ETFE).
  • ETFE ethylene-tetrafluoroethylene
  • the receptacle is a container that is conventionally intended for the storage and/or administration of a liquid medicament, like a vial, a syringe, an ampoule, a carpoule, or an infusion container, wherein the liquid formulation of G-CSF according to the present invention is particularly advantageous for the use in ready-to-use syringes and ampoules.
  • the liquid formulation is present in the syringe or in the ampoule at a concentration, in terms of concentration of G-CSF, of 0.3 mg in 0.5 ml or 0.48 mg in 0.8 ml.
  • the G-CSF liquid medicament according to the present invention can be prepared for immediate administration, for example in a kit.
  • the present invention therefore also relates to a kit for the parenteral administration of G-CSF, comprising one or more of the above-described receptacles, preferably along with instructions for storage and/or administration.
  • a kit for the parenteral administration of G-CSF comprising one or more of the above-described receptacles, preferably along with instructions for storage and/or administration.
  • the administration of G-CSF at a dosage of 5 to 30 ⁇ g/kg body weight will be provided, wherein higher or lower dosages may be indicated, however, depending on the medical indication and the stage of the disease.
  • 5 syringes or ampoules are provided in the kit according to the present invention, optionally more, like 7 syringes or ampoules, for example in case the daily administration is intended to last for one week.
  • the kit according to the present invention advantageously has safety compartments for syringes and for injection and/or infusion needles, respectively.
  • discharge aids for the needles and prepared or pre-fitted sealing caps are also to be considered.
  • the G-CSF liquid formulations according to the present invention are stable over a long time period, in particular at about 5° C., preferably over a period of at least 4 weeks. Therefore, the liquid formulations, receptacles and kits according to the present invention can advantageously be stored in a conventional refrigerator.
  • the solutions of G-CSF used in the Examples were prepared by dissolving the above-described excipients in water for injection purposes, adding the indicated amounts of G-CSF and, if required, exactly adjusting the pH value to the desired value using a small amount of buffer component.
  • the solutions are subsequently filtered through suitable sterilized membrane filters having a pore width of 0.2 ⁇ m, filled in sterilized glass injection vials of hydrolytic class I and sealed with sterilized teflonized rubber plugs. Filling is preferably performed in nitrogen atmosphere.
  • the experimental preparations of G-CSF are stored in sealed and crimped vials under exclusion of light at defined storage temperatures and subsequently tested for protein purity and the occurrence of oxidized forms, aggregates and dimers using standard techniques like UV spectroscopy, reversed-phase HPLC with C4 and C18 stationary phase, or size exclusion chromatography (SEC HPLC), isoelectric focusing, SDS-PAGE under thiol reducing and non-reducing conditions with subsequent silver staining and Western immunoblot analyses; for information on the techniques mentioned see, e.g., the examples of WO 94/14466, the disclosure of which is incorporated herein by reference.
  • the G-CSF formulations of the present invention as specified in Table 1 are characterized in that the relative content of oxidized species is below 1%, while this threshold value was exceeded in the control samples having a surfactant content of 0.008% and more, which leads to the conclusion that such solutions cannot be considered as candidate medicaments.
  • liquid formulations according to the present invention was tested in three phase III clinical studies in cancer patients, wherein, inter alia, the patients' reactions in the vicinity of the injection site were examined. Here, an examination of swelling, redness, skin bleeding, sensitivity to pressure and other symptoms occurring at the injection site was performed.
  • the G-CSF formulation of the present invention was selected according to the indications of experimental preparation Ha (XM02) in Table 1 and was processed at a dosage of 5 ⁇ g/kg body eight per day.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
US12/675,776 2007-08-27 2008-08-27 Stable liquid formulations of G-CSF Expired - Fee Related US8562967B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP07016763 2007-08-27
DE102007040932A DE102007040932A1 (de) 2007-08-27 2007-08-27 Flüssigformulierung von G-CSF
EP07016763 2007-08-27
DE102007040932.1 2007-08-27
EP07016763.0 2007-08-27
DE102007040932 2007-08-27
PCT/EP2008/007012 WO2009027076A1 (de) 2007-08-27 2008-08-27 Flüssigformulierung von g-csf

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/007012 A-371-Of-International WO2009027076A1 (de) 2007-08-27 2008-08-27 Flüssigformulierung von g-csf

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/044,852 Division US8946161B2 (en) 2007-08-27 2013-10-02 Method of treatment using stable liquid formulation of G-CSF

Publications (2)

Publication Number Publication Date
US20100216698A1 US20100216698A1 (en) 2010-08-26
US8562967B2 true US8562967B2 (en) 2013-10-22

Family

ID=39745039

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/675,776 Expired - Fee Related US8562967B2 (en) 2007-08-27 2008-08-27 Stable liquid formulations of G-CSF
US14/044,852 Expired - Fee Related US8946161B2 (en) 2007-08-27 2013-10-02 Method of treatment using stable liquid formulation of G-CSF
US14/593,862 Expired - Fee Related US9468685B2 (en) 2007-08-27 2015-01-09 Methods of preparing a liquid formulation of G-CSF

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/044,852 Expired - Fee Related US8946161B2 (en) 2007-08-27 2013-10-02 Method of treatment using stable liquid formulation of G-CSF
US14/593,862 Expired - Fee Related US9468685B2 (en) 2007-08-27 2015-01-09 Methods of preparing a liquid formulation of G-CSF

Country Status (20)

Country Link
US (3) US8562967B2 (es)
EP (2) EP2076243B9 (es)
JP (2) JP2010536906A (es)
KR (1) KR20100044261A (es)
CN (1) CN101795670A (es)
AU (1) AU2008291309B2 (es)
BR (1) BRPI0815280A2 (es)
CA (1) CA2697376C (es)
CY (1) CY1115815T1 (es)
DK (1) DK2076243T3 (es)
ES (1) ES2524454T3 (es)
HR (1) HRP20141217T1 (es)
IL (1) IL204118A (es)
MX (1) MX2010002348A (es)
NZ (1) NZ583999A (es)
PL (1) PL2076243T3 (es)
PT (1) PT2076243E (es)
SI (1) SI2076243T1 (es)
UA (1) UA100245C2 (es)
WO (1) WO2009027076A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291725B2 (en) * 2016-10-31 2022-04-05 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2399572A1 (en) * 2010-06-22 2011-12-28 Sandoz AG Long-term storage of non-glycosylated recombinant human G-CSF
CN106132415A (zh) * 2014-03-20 2016-11-16 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
US11896037B2 (en) 2016-08-03 2024-02-13 Temple University-Of The Commonwealth System Of Higher Education Microencapsulation of active agents

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987001132A1 (en) 1985-08-23 1987-02-26 Kirin-Amgen, Inc. Production of pluripotent granulocyte colony-stimulating factor
EP0373679A2 (en) 1988-12-16 1990-06-20 Amgen Inc. Stabilized hydrophobic protein formulations
WO1993003744A1 (de) 1991-08-15 1993-03-04 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanproteinhaltigen, konservierten arzneimitteln für infusions- oder injektionszwecke
US5284656A (en) * 1991-03-15 1994-02-08 Amgen Inc. Pulmonary administration of granulocyte colony stimulating factor
WO1994014466A1 (de) 1992-12-18 1994-07-07 Boehringer Mannheim Gmbh Lagerstabile wässrige pharmazeutische zubereitungen von g-csf
WO1994014465A1 (de) 1992-12-18 1994-07-07 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische zubereitungen von g-csf
EP0988861A1 (en) 1998-08-17 2000-03-29 Pfizer Products Inc. Stabilized protein compositions
EP1060746A1 (en) 1998-03-06 2000-12-20 Chugai Seiyaku Kabushiki Kaisha Protein-free preparations
EP1129720A2 (en) 2000-02-29 2001-09-05 Pfizer Products Inc. Stabilized granulocyte colony stimulating factor
WO2004001056A1 (en) 2002-06-24 2003-12-31 Dr. Reddy's Laboratories Ltd. Process for preparing g-csf
WO2005039620A1 (de) 2003-10-20 2005-05-06 Hexal Biotech Forschungs Gmbh Stabile wässrige g-csf-haltige zusammensetzungen
WO2005042024A1 (en) 2003-11-04 2005-05-12 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising granulocyte-colony stimulating factor
WO2007099145A1 (de) 2006-03-01 2007-09-07 Bioceuticals Arzneimittel Ag G-csf-flüssigformulierung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236819A (en) 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987001132A1 (en) 1985-08-23 1987-02-26 Kirin-Amgen, Inc. Production of pluripotent granulocyte colony-stimulating factor
EP0373679A2 (en) 1988-12-16 1990-06-20 Amgen Inc. Stabilized hydrophobic protein formulations
US5284656A (en) * 1991-03-15 1994-02-08 Amgen Inc. Pulmonary administration of granulocyte colony stimulating factor
WO1993003744A1 (de) 1991-08-15 1993-03-04 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanproteinhaltigen, konservierten arzneimitteln für infusions- oder injektionszwecke
US5503827A (en) 1991-08-15 1996-04-02 Boehringer Mannheim Gmbh Process for the production of multi-dose pharmaceutical preparations containing isolated or recombinantly produced human protein for infusion or injection purposes
WO1994014466A1 (de) 1992-12-18 1994-07-07 Boehringer Mannheim Gmbh Lagerstabile wässrige pharmazeutische zubereitungen von g-csf
WO1994014465A1 (de) 1992-12-18 1994-07-07 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische zubereitungen von g-csf
US5919757A (en) 1992-12-18 1999-07-06 Boehringer Mannheim Gmbh Aqueous pharmaceutical preparations of G-CSF with a long shelf life
US5919443A (en) 1992-12-18 1999-07-06 Boehringer Manheim Gmbh Stable lyophilized pharmaceutical preparations of G-CSF
EP1060746A1 (en) 1998-03-06 2000-12-20 Chugai Seiyaku Kabushiki Kaisha Protein-free preparations
EP0988861A1 (en) 1998-08-17 2000-03-29 Pfizer Products Inc. Stabilized protein compositions
EP1129720A2 (en) 2000-02-29 2001-09-05 Pfizer Products Inc. Stabilized granulocyte colony stimulating factor
WO2004001056A1 (en) 2002-06-24 2003-12-31 Dr. Reddy's Laboratories Ltd. Process for preparing g-csf
WO2005039620A1 (de) 2003-10-20 2005-05-06 Hexal Biotech Forschungs Gmbh Stabile wässrige g-csf-haltige zusammensetzungen
US20080026046A1 (en) * 2003-10-20 2008-01-31 Hexal Biotech Forshungs Gmbh Stable Aqueous G-Csf Conatining Compositions
WO2005042024A1 (en) 2003-11-04 2005-05-12 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising granulocyte-colony stimulating factor
WO2007099145A1 (de) 2006-03-01 2007-09-07 Bioceuticals Arzneimittel Ag G-csf-flüssigformulierung
DE202006020194U1 (de) * 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
EP1988913A1 (de) 2006-03-01 2008-11-12 Bioceuticals Arzneimittel AG G-csf-flüssigformulierung
DE202007018618U1 (de) 2006-03-01 2008-12-11 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
US20090247450A1 (en) 2006-03-01 2009-10-01 Michael Mack G-csf liquid formulation

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
Communication pursuant to Article 94(3) EPC dated May 21, 2012 from European Patent Application No. 08 785 714.0-1219.
Declaration of Dr. Walter Hinderer submitted in European Patent Application 08785714.0 with Exhibit A: (a comparative analysis of G-CSF monomer and dimer formation following storage for four weeks at 40° C.) and Exhibit B: (Assessment Report on Ratiograstim).
English translation of Examination report in German priority patent application DE 10 2007 040 932.1, Aug. 7, 2008.
English translation of Examination report in parallel European patent application No. 08 785 714.0, Apr. 8, 2010.
English translation of further petition by ratiopharm GmbH and CT Arzneimittel GmbH in opposition to proceedings concerning European patent EP 1 988 913 B1, Apr. 23, 2009.
English translation of petition in Utility Model Cancellation Proceedings concerning German Utility Model DE 20 2007 018 618 U1, Jan. 25, 2010.
English translation of the opposition petition by ratiopharm GmbH and CT Arzneimittel GmbH in opposition to proceedings concerning European patent EP 1 988 913 B1, Apr. 23, 2009.
Entry from the European Patent Office , related to WO2007099145, accessed Jun. 5, 2012. *
European Medicines Agency Assessment Report for RatioGrastim, Doc Ref EMEA/502481/2008.
Examination report in German priority patent application DE 10 2007 040 932.1, Aug. 7, 2008.
Examination report in parallel European patent application No. 08 785 714.0, Apr. 8, 2010.
Extract from "Rote Liste", 2005, ECV Edition Cantor Verlag, Aulendorf, pp. 51030-51036.
Extract from AHFS-Drug Information (2001) "Filgrastim", pp. 1454-1463.
Extract from AHFS—Drug Information (2001) "Filgrastim", pp. 1454-1463.
Herman et al., "Formulation, Characterization, and Stability of Neupogen (Filgrastim), a Recombinant Human Granulocyte-Colony Stimulating Factor"; Perlman and Wang, Eds. (1996), pp. 303-328.
Opposition against EP 1 988 913 B1 by Hospira UK Ltd., Jan. 25, 2010.
Opposition against EP 1 988 913 B1 by ratiopharm GmbH and CT Arzneimittel GmbH, Apr. 23, 2009.
Opposition against EP 1 988 913 B1 by Sandoz AG, Jan. 20, 2010.
Opposition against EP 1 988 913 B1 by Teva Pharmaceuticals Industries Ltd., Apr. 22, 2009.
Petition in Utility Model Cancellation Proceedings concerning German Utility Model DE 20 2007 018 618 U1, Sep. 23, 2009.
Ratiopharm Press Release: "Biosimilar Ratiograstim received EMEA approval", Sep. 2008.
Translation of International Report on Patentability issued Apr. 8, 2010 for PCT/E2008/007012.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291725B2 (en) * 2016-10-31 2022-04-05 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition

Also Published As

Publication number Publication date
HRP20141217T1 (hr) 2015-02-27
EP2471510A1 (de) 2012-07-04
PT2076243E (pt) 2014-12-05
EP2076243A1 (de) 2009-07-08
CA2697376C (en) 2016-07-19
CN101795670A (zh) 2010-08-04
AU2008291309A1 (en) 2009-03-05
WO2009027076A1 (de) 2009-03-05
US20140030214A1 (en) 2014-01-30
MX2010002348A (es) 2010-07-30
JP2015038111A (ja) 2015-02-26
EP2076243B1 (de) 2014-10-01
DK2076243T3 (da) 2015-01-05
US8946161B2 (en) 2015-02-03
US20100216698A1 (en) 2010-08-26
AU2008291309B2 (en) 2013-10-17
ES2524454T3 (es) 2014-12-09
PL2076243T3 (pl) 2015-04-30
JP2010536906A (ja) 2010-12-02
NZ583999A (en) 2011-10-28
CY1115815T1 (el) 2017-01-25
US20150125420A1 (en) 2015-05-07
CA2697376A1 (en) 2009-03-05
BRPI0815280A2 (pt) 2018-11-27
SI2076243T1 (sl) 2015-01-30
EP2076243B9 (de) 2015-01-14
US9468685B2 (en) 2016-10-18
KR20100044261A (ko) 2010-04-29
IL204118A (en) 2014-11-30
UA100245C2 (uk) 2012-12-10

Similar Documents

Publication Publication Date Title
RU2311922C2 (ru) Свободные от цинка и обедненные цинком инсулиновые композиции с повышенной стабильностью
ES2224290T5 (es) Formulaciones l�?quidas estables de interferón.
CA2151732C (en) Stable lyophilized pharmaceutical preparations of g-csf
KR100266146B1 (ko) 긴 보장기간을 갖는 g-csf의 수성 약제 조성물
JP5941496B2 (ja) 成長ホルモン製剤
KR101084412B1 (ko) 코팅된 제약 용기 내 안정화된 액상 단백질 제제
US20180036411A1 (en) Stable Formulation of Insulin Glulisine
KR102662530B1 (ko) 양극성 용매에서 안정한 치료 제형들의 제조방법.
US9468685B2 (en) Methods of preparing a liquid formulation of G-CSF
KR20190127651A (ko) 데옥시콜릭산을 포함하는 약학 조성물
CA2521560A1 (en) Hsa-free stabilized interferon liquid formulations
JP6869255B2 (ja) 凍結医薬製剤およびその使用
RU2572800C1 (ru) Новый состав, содержащий конъюгат пэг и интерферон-альфа-2бета, обладающий сниженной болезненностью при введении
AU2022386352A1 (en) Preserved formulations
DE202007018629U1 (de) Flüssigformulierung von G-CSF

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOGENERIX AG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HINDERER, WALTER;LUBENAU, HEINZ;SIGNING DATES FROM 20100406 TO 20100411;REEL/FRAME:024247/0579

AS Assignment

Owner name: BIOGENERIX AG, GERMANY

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED ON REEL 024247 FRAME 0579. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNEE ADDRESS IS GRAF-ARCO-STR. 3, 89079 ULM, GERMANY;ASSIGNORS:HINDERER, WALTER;LUBENAU, HEINZ;SIGNING DATES FROM 20100406 TO 20100411;REEL/FRAME:029178/0217

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: BIOGENERIX GMBH, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:BIOGENERIX AG;REEL/FRAME:032815/0845

Effective date: 20120712

Owner name: RATIOPHARM GMBH, GERMANY

Free format text: MERGER;ASSIGNOR:BIOGENERIX GMBH;REEL/FRAME:032813/0427

Effective date: 20130724

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20211022